Insider Transactions in Q4 2024 at Prelude Therapeutics Inc (PRLD)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
5,000
+3.39%
|
$5,000
$1.21 P/Share
|
|
Dec 30
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+6.78%
|
$10,000
$1.2 P/Share
|
|
Dec 23
2024
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
60,000
+13.71%
|
$60,000
$1.37 P/Share
|
|
Dec 20
2024
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
3,075
+0.96%
|
$3,075
$1.15 P/Share
|
|
Dec 19
2024
|
Bryant David Lim CLO, Interim CFO, Corp Sec. |
BUY
Open market or private purchase
|
Direct |
25,000
+47.71%
|
$0
$0.91 P/Share
|
|
Dec 19
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
6,888
+5.12%
|
$0
$0.89 P/Share
|
|
Dec 18
2024
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+7.89%
|
$0
$0.93 P/Share
|
|
Oct 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,349
-5.02%
|
$6,698
$2.0 P/Share
|
|
Oct 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+12.33%
|
-
|